Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc develops cancer medicines based on its proprietary ProTide technology, with news centered on the ADR-listed clinical-stage biopharmaceutical company’s oncology pipeline and corporate updates. Recurring releases describe NUC-7738, a novel anti-cancer agent being studied as a monotherapy in advanced solid tumors and with pembrolizumab in melanoma, and NUC-3373, a 5-fluorouracil-derived new chemical entity being studied with pembrolizumab and docetaxel in advanced solid tumors and lung cancer.
Company updates also cover clinical and translational data presentations, patent protection for NUC-7738, quarterly and annual financial results, cash runway commentary, executive and board changes, and Nasdaq continued-listing matters for NuCana’s American depositary shares.
NuCana plc (NASDAQ: NCNA) announced that Hugh Griffith, CEO, and Don Munoz, CFO, will present at the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. A pre-recorded presentation will be available for replay starting November 23, 2020. NuCana focuses on enhancing cancer treatment through its ProTide technology, developing innovative medicines like Acelarin and NUC-3373, derived from standard chemotherapy agents. These candidates aim to overcome cancer resistance mechanisms, with several in various phases of clinical trials.
NuCana plc (NASDAQ: NCNA) announced its participation in the Jefferies Virtual London Healthcare Conference. CEO Hugh Griffith and CFO Don Munoz will present on November 18, 2020, at 11:45 AM GMT, with a live webcast available for replay on their website.
NuCana is focused on developing improved cancer therapies using its ProTide technology. Their pipeline includes ProTides Acelarin, NUC-3373, and NUC-7738, targeting various cancers to overcome resistance mechanisms and enhance efficacy.
NuCana plc appoints Bali Muralidhar, M.D., Ph.D. to its Board of Directors, enhancing its leadership team as it advances its ProTide pipeline targeting cancer treatment. This follows a successful $80 million public offering, with significant investment from Abingworth, a prominent life sciences investment firm. The new funding is expected to accelerate the development of ProTides, which include three products currently in clinical trials. Management believes these advancements could significantly improve patient outcomes in oncology.
NuCana plc (NASDAQ: NCNA) reported promising results for its clinical programs at ESMO 2020.
The Phase Ib study of NUC-3373 in advanced colorectal cancer showed its ability to stabilize disease and enhance progression-free survival in heavily pre-treated patients. Moreover, NUC-7738 exhibited anti-cancer activity with a favorable tolerability profile in advanced solid tumors. NuCana aims to replace standard cancer treatments with its ProTide technology, evidenced by these encouraging early results.
NuCana plc has announced a public offering of 15,555,556 American Depositary Shares (ADSs) at $4.50 each, aiming to raise approximately $70 million before expenses. The underwriters also hold a 30-day option for an additional 2,333,333 ADSs. All proceeds from the offering, expected to close around September 21, 2020, will enhance NuCana’s pipeline, which includes treatments for cancer using their ProTide technology. The company emphasizes its commitment to improving therapeutic outcomes for patients with cancer.
NuCana is initiating an underwritten public offering of its American Depositary Shares (ADSs), each representing one ordinary share. The underwriters have a 30-day option to purchase an additional 15% of the ADSs at the public offering price. The offering is part of a previously declared effective registration statement and is subject to market conditions. No assurance can be provided regarding the completion or terms of the offering. Jefferies, Cowen, William Blair, and Truist Securities are the joint book-running managers.
NuCana plc (NASDAQ: NCNA) announced its financial results for Q2 2020, reporting a net loss of £6.1 million compared to £4.5 million in Q2 2019. The cash position was stable at £47.8 million. CEO Hugh Griffith highlighted the company's ongoing clinical trials, including the Phase III study of Acelarin in biliary tract cancer, and advancements in NUC-3373 and NUC-7738. Positive data presented at the American Association for Cancer Research indicated the ProTides' potential to enhance immune checkpoint inhibitors. A cash runway is expected to last into Q4 2021.
NuCana plc (NASDAQ: NCNA) reported Q1 2020 financial results, revealing a net loss of £4.0 million, an improvement from £5.4 million the previous year. As of March 31, 2020, cash and equivalents stood at £47.6 million, down from £52.0 million at the end of 2019. Following a temporary pause in clinical trials due to COVID-19, patient enrollment has resumed. The company expects its cash runway to last until at least Q4 2021, aided by cost-saving measures. Upcoming milestones include continued enrollment in various clinical studies and data reporting for several ProTide therapeutics.
NuCana (NASDAQ: NCNA) has resumed patient enrollment in multiple clinical studies following a temporary pause due to COVID-19. The Phase III trial of Acelarin plus cisplatin for biliary tract cancer (NuTide:121) reopened on May 5, 2020, and new trials for NUC-3373 and NUC-7738 are now also active. CEO Hugh S. Griffith emphasized the importance of advancing cancer treatments amidst the pandemic. The studies are underway in various countries including Australia, Canada, and the UK, highlighting NuCana's commitment to developing innovative cancer therapies.
NuCana plc (NASDAQ:NCNA) announced that two abstracts detailing non-clinical studies on its ProTides, Acelarin (NUC-1031) and NUC-3373, have been selected for presentation at the AACR Annual Meeting 2020 from June 22-24, 2020. Acelarin has shown potential as an immunomodulatory agent, increasing PD-L1 expression and releasing DAMPs in lung cancer cells. Meanwhile, NUC-3373 induces ER stress and DAMP release in colorectal cancer cells. Both candidates may enhance the efficacy of immune checkpoint inhibitors in cancer treatment.